Humanitarian Device Exemptions (HDE) 101 Elizabeth Hillebrenner, MSE Biomedical Engineer IDE and HDE Program Staff Center for Devices and Radiological.

Slides:



Advertisements
Similar presentations
The Role of the IRB An Institutional Review Board (IRB) is a review committee established to help protect the rights and welfare of human research subjects.
Advertisements

Investigational Device Exemption (IDE) Overview for IRBs
Regulatory Pathway for Platform Technologies
Investigational Device Exemptions 21 CFR Part 812
Investigational Device Exemptions (IDE) CFR Title 21, Part 812
1 Developed by: U-MIC To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the.
Overview of FDA Device Regulations
What is involved? What are your responsibilities? May 2013: Research Institute, Clinical Research Administration Investigational New Drug Application (IND)
"Determining the Regulatory Pathway to Market" Classification Heather S. Rosecrans Director, 510(k) Staff Office of Device Evaluation Center for Devices.
SOP Melody Lin, Ph.D. Deputy Director, Office for Human Research Protections Director, International Activities Santiago, Chile August.
Rare Diseases and FDASIA
FDA Regulated Research:
IRB Review of Device Research and Other Clinical Uses of Devices
510k Submission Overview Myraqa, Inc. August 22, 2012.
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development IND Regulatory.
Single Use Expanded Access IND/IDE: FDA and IRB Requirements Before and After Use IRB Webinar October 9,2014.
Introduction to Regulation
Medical Device Submissions
IRB PRESENTATION REGULATORY PATHWAYS HDE – PMA William Hellenbrand MD Director – Pediatric Cardiology Columbia University College of Physicians & Surgeons.
Columbia University IRB IRB 101 September 21, 2005 George Gasparis, Executive Director, CU IRB Asst. V.P. and Sr. Asst. Dean for Research Ethics.
CUMC IRB Investigator Meeting Special IND/IDE Considerations: Emergency Use of Investigational Product Compassionate Use & Emergency Research July 21,
Special Topics in IND Regulation
The FDA Landscape AdvaMed September 2008 Judith K. Meritz
Investigational New Drug Application 21 CFR Part 312 A Review for OCRA US RAC Study Group September 2005 Ginger Clasby, MS Promedica International
+ Medical Devices Approval Process. + Objectives Define a medical device Be familiar with the classification system for medical devices Understand the.
Mrs. Brandi Robinson Office of New Animal Drug Evaluation Center for Veterinary Medicine Regulating Animal Drugs.
Radiological Devices Advisory Committee Meeting November 18, 2009 John A. DeLucia iCAD, Inc.
FDA Resources and Meetings FDA/EMA Orphan Designation and Grant Workshop Silver Spring, Maryland FDA Campus (White Oak) October 12, 2012 Bill Sutton Deputy.
1 THE UNIQUE ROLES OF IRB IN MEDICAL DEVICE CLINICALL TRIAL Chiu Lin, Ph.D. CITI, May, 2009 CITI, May, 2009.
Device Research Presented by Marian Serge, R.N.. Goals Identify devices Recognize difference between significant risk (SR) and non- significant risk (NSR)
Adverse Events, Unanticipated Problems, Protocol Deviations & other Safety Information Which Form 4 to Use?
Nonclinical Studies Subcommittee Advisory Committee for Pharmaceutical Science CMC Issues for Screening INDs Eric B. Sheinin, Ph.D. Acting Deputy Director.
The Medical Device Pathway as a Legal Onramp for Futuristic Persons THE FUTURE T HE M EDICAL D EVICE P ATHWAY AS A L EGAL.
Reporting Unanticipated Problems and Adverse Events: A Change in Policy Mary A. Banks RN, BS, BSN Director, BUMC IRB Wednesday, November 14, 2007.
Investigational New Drug Application (IND)
Human Research Protection Program 101 March 19-20, 2007 Cincinnati, Ohio.
Planned Emergency Research Exception from Informed Consent Requirements September 2007.
INDs : Does My Study Need One? Edith Paal UAMS Office of Research Compliance August 22, 2003.
Key Compliance Risks in Clinical Trials Kathleen Meriwether Principal, ERNST & YOUNG, LLP Fraud Investigation & Dispute Services.
PATRICIA KERBY, MPA HUMAN SUBJECTIONS PROTECTION COMPLIANCE OFFICER OFFICE OF RESEARCH COMPLIANCE What are the FDA’s expectations in 2010?
Humanitarian Use Devices September 23, 2011 Theodore Stevens, MS, RAC Office of Cellular, Tissue and Gene Therapies Center for Biologics Evaluation and.
“513(g)s” Requests for Information Lawrence “Jake” Romanell, RM (AAM) Office of Device Evaluation Center for Devices and Radiological Health.
Welcome New IRB Members! Today we will discuss: Your Role in the IRB: What to Know The IRB Review Process Resources Human Research Protections.
Module C FDA Regulations Regulatory Documents Patricia E. Koziol 1Module C Final Version 10-apr-2010.
Investigational Devices and Humanitarian Use Devices June 2007.
June 23, 2005Abiomed, H DRAFT. CIRCULATORY SUPPORT DEVICES PANEL Thursday, June 23, 2005 Abiomed, Inc. Abiocor® Implantable Replacement Heart HDE.
General Regulatory Issues in the Development of Drugs Intended for Treatment of Chronic Illness Sharon Hertz, M.D. Medical Officer Division of Anesthetic,
October 28, F OOD AND DRUG ADMINISTRATION AMENDMENTS ACT OF 2007 (FDAAA) and Risk Evaluation and Mitigation Strategies (REMS) Presented to the Ninth.
Overview of Premarket Approval (PMA) Program
HUD and Emergent Use Walter Kraft. Device Classification Significant risk – Often involve an invasive procedure for implantation or use – Requires IDE.
GU Advisory Panel Meeting Nocturnal Home Hemodialysis Draft Carolyn Y. Neuland, Ph.D. Chief, Gastroenterology and Renal Devices Branch Division of Reproductive,
Human Specimen Repositories Requirements of 21 CFR Parts 50 & 56 PRIM & R May 5, 2004 Sally A. Hojvat, Ph.D. Director of Microbiology Devices Office of.
Radiology Advisory Panel Meeting Radiology Advisory Panel Meeting Computer-Assisted Detection (CADe) Devices Joyce M. Whang Deputy Division Director Radiological.
Device Updates in FDASIA MDUFA III RA SAIC – 9 th April 2013 Karen Jaffe, MS, MBA, RAC or
1 IND Applications for Academic Clinical Investigations John Marler, MD US Food and Drug Administration New Hampshire Avenue White Oak, MD
Complaint Handling Medical Device Reporting May 19, 2016 Rita Harden, Director Customer Relations & Regulatory Reporting.
GCP AND MEDICAL DEVICES
What Are the FDA Requirements for Submitting an IDE?
Division of Cardiovascular Devices
FDA’s IDE Decisions and Communications
How to Put Together an IDE Application
Balancing Pre and Postmarket Requirements Different Scenarios
To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the screen changes and you.
Reasonable Assurance of Safety and Effectiveness: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division.
Adverse Event Reporting: Trials and Tribulations
Medical Device Regulatory Essentials: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.
To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the screen changes and you.
Streamlining IRB Procedures for Expanded Access
FDA Resources and Meetings
Opening an IND: Investigator Perspective
Presentation transcript:

Humanitarian Device Exemptions (HDE) 101 Elizabeth Hillebrenner, MSE Biomedical Engineer IDE and HDE Program Staff Center for Devices and Radiological Health

Humanitarian Use Device device intended to benefit patients in the treatment and diagnosis of diseases or conditions that affect fewer than 4,000 individuals in the US designation of HUD status may be achieved through application to OOPD marketing approval of a device with HUD status may be achieved through application to CDRH or CBER 2

Marketing a HUD PMA PreMarket Approval Submission Does not require HUD designation from OOPD Requires demonstration of a reasonable assurance that the device is safe and effective for the proposed intended use No limitation on profit User fee (with exceptions) HDE Humanitarian Device Exemption Submission Requires HUD designation from OOPD Requires demonstration of a reasonable assurance that the device is safe and provides probable benefit for the proposed intended use Some profit limitations No user fee 3

Threshold for Approval PMA Effectiveness “There is reasonable assurance that a device is effective when it can be determined, based upon valid scientific evidence, that in a significant portion of the target population, the use of the device for its intended uses and conditions of use, when accompanied by adequate directions for use and warnings against unsafe use, will provide clinically significant results.” 21 CFR HDE Probable Benefit “The device will not expose patients to an unreasonable or significant risk of illness or injury and the probable benefit to health from the use of the device outweighs the risk of injury or illness from its use, taking into account the probable risks and benefits of currently available devices or alternative forms of treatment.” FD&C Act Section 520(m) (No regulatory definition) 4

Threshold for Approval PMA Effectiveness Data The valid scientific evidence used to determine the effectiveness of a device shall consist principally of well- controlled investigations 21 CFR HDE Probable Benefit Data Summaries, conclusions, and results of all clinical experience or investigations (whether adverse or supportive) reasonably obtainable by the applicant that are relevant to an assessment of the risks and probable benefits of the device 21 CFR

HDE Profit Limitations Evolution over time –1990 SMDA: NO profit eligibility –2007 FDAA: profit eligibility for newly approved HDE devices labeled for pediatrics –2012 FDASIA: expansion of profit eligibility beyond pediatrics and to previously approved HDEs Determined by Annual Distribution Number (ADN) –Number of devices that can be sold per year at a profit 6

HDE Profit Eligibility FDAAA (2007) If the device is intended for the treatment or diagnosis of a disease or condition that occurs in pediatric patients or in a pediatric subpopulation, and such device is labeled for use in pediatric patients or in a pediatric subpopulation in which the disease or condition occurs. FDASIA (2012) If the device is intended for the treatment or diagnosis of a disease or condition that occurs in pediatric patients or in a pediatric subpopulation, and such device is labeled for use in pediatric patients or in a pediatric subpopulation in which the disease or condition occurs; or does not occur in pediatric patients; or occurs in pediatric patients in such numbers that the development of the device for such patients is impossible, highly impracticable, or unsafe. 7

HDE Profit Eligibility FDAAA (2007) Applies only to newly approved HDEs ADN capped at 3,999 ADN = product of: –# of devices reasonably necessary to treat, diagnose, or cure an individual –# of individuals affected by the disease or condition the HUD is intended to treat, diagnose, or cure and that are likely to use the device FDASIA (2012) May apply to previously approved HDEs ADN not capped ADN = product of: –# of devices reasonably necessary to treat, diagnose, or cure an individual –4,000 8

Submitting an HDE Submit to Document Mail Center (DMC) –Per FDASIA, must include e copy No user fee 75 day review time –May be placed on hold during this time if additional information is needed 9 U.S. Food and Drug Administration Center for Devices & Radiological Health Document Mail Center – WO66 – G New Hampshire Ave. Silver Spring, MD Document Control Center (HFM-99) Center for Biologics Evaluation & Research Food and Drug Administration 1401 Rockville Pike, Suite 200N Rockville, MD

HDE Submission Contents Statutory Requirements (520(m)) Letter from OOPD granting HUD designation Explanation why device would not be otherwise available Statement that no comparable device exists (through a 510(k) or PMA) Discussion of risks and benefits of currently available devices or alternative forms of treatment in the US Demonstration of safety and probable benefit 10

HDE Submission Contents Regulatory Requirements ( ) PMA requirements –Exception: Requirement for well controlled investigations as valid scientific evidence of effectiveness replaced with requirement for: “summaries, conclusions, and results of all clinical experience or investigations (whether adverse or supportive) reasonably obtainable by the applicant that are relevant to an assessment of the risks and probable benefits of the device” –Includes manufacturing information demonstrating compliance with QS regulations 11

HDE Submission Contents Regulatory Requirements ( ) Labeling with the following statement: “Humanitarian Device. Authorized by Federal law for use in the [treatment or diagnosis] of [specify disease or condition]. The effectiveness of this device for this use has not been demonstrated” The amount to be charged for the device. –If >$250, verification that it does not exceed costs of the device's research, development, fabrication, and distribution. 12

HDE Post Approval Considerations IRB approval required at each institution prior to use –Exception: emergency use cases, approved IDE clinical studies Records maintenance (subject to inspection) –Facilities shipped to –IRB correspondence Modifications require prior approval of an HDE Supplement by FDA 13

HDE Post Approval Considerations Annual Reports –PMA annual reporting requirements –Annual incident reassessment re target population –Number of devices sold/used –Summary of clinical experience since approval –Summary of device changes Post Approval Study –if required as a condition of approval 14

HDE Post Approval Considerations Medical Device Reporting (MDR) of adverse events Annual review of adverse events related to pediatric devices by Pediatric Advisory Committee –Office of Pediatric Therapeutics Approval may be withdrawn if a PMA is approved for a different device with same indications 15

Common Points of Confusion HDE is marketing approval –Not investigational –Exempt from effectiveness requirements IRB approval required for all uses –IRB may also approve “off-label” uses Informed consent not required by FDA –May be required by state, local, institutional, or IRB requirement 16

Common Points of Confusion There can be multiple HDEs for the same indication from different sponsors Clinical trial for new indication requires an IDE if the device is SR (so far, all HDEs are SR) 17

Helpful References FD&C Act Section 520(m) title21/html/USCODE-2010-title21-chap9-subchapV-partA- sec360j.htm 21 CFR Section 814 Subpart H RPart=814&showFR=1&subpartNode=21: Guidance Document (will be updated soon) ce/GuidanceDocuments/ucm pdf Device Advice arketYourDevice/PremarketSubmissions/HumanitarianDeviceExemption/def ault.htm Summaries of Safety and Probable Benefit (SSPBs) of approved HDEs 18

HDE Contacts IDE/HDE Staff Review Branch/Division Leadership dicalProductsandTobacco/CDRH/CDRHOffices/ucm htm#ODE 19